Accelerated Stability Testing: What It Proves and What It Cannot
There is a piece of arithmetic that circulates in this category and it is worth naming before anything else. It says that three months at 40 °C is equivalent to two years at 25 °C, so a peptide that survives an oven for a quarter is good for two years in a freezer. The number changes depending on who is repeating it — sometimes it is six months, sometimes three years — but the shape is always the same: a short hot study standing in for a long cold one.
No stability guideline says this. What the guidelines actually say is narrower, more useful, and considerably less flattering to the marketing copy built on top of it. An accelerated study is a comparison, not a prediction. It is designed to tell you whether a material degrades faster than an acceptance criterion allows under a defined stress, and to tell you which analytical methods are capable of seeing that degradation when it happens. It is not designed to produce a shelf life, and under the harmonized rules it is explicitly not permitted to produce one on its own.
For a US laboratory buying research-grade peptide material, that distinction has a practical edge. Nothing on a research certificate is a stability result, and the reason is not that the supplier cut a corner. It is that the study which would generate one takes longer than the material’s commercial life.
What ICH actually specifies
The controlling document for small-molecule drug substances and products is ICH Q1A(R2). Its storage-condition table is short and specific. Long-term studies run at 25 °C ± 2 °C / 60% RH ± 5% RH, or alternatively 30 °C ± 2 °C / 65% RH ± 5% RH, with a minimum of twelve months of data at submission. Intermediate studies run at 30 °C ± 2 °C / 65% RH ± 5% RH for six months. Accelerated studies run at 40 °C ± 2 °C / 75% RH ± 5% RH, also for six months.
Note what those conditions are: temperature and relative humidity, both controlled, both stated with tolerances. An “accelerated” study in the ICH sense is not a hot cupboard. Humidity is a co-variable of equal standing, which matters enormously for a lyophilized solid, where sorbed water plasticizes the amorphous cake and changes the molecular mobility that governs solid-state reaction rates in the first place.
Q1A(R2) also defines what counts as a failure. For a drug product, significant change includes a 5% change in assay from the initial value, or any degradation product exceeding its acceptance criterion, alongside failures of appearance, pH or dissolution depending on the form. And it defines what happens next: where significant change occurs during six months of accelerated testing, the application must carry a minimum of six months of data from a twelve-month study at the intermediate condition. The accelerated study, in other words, does not resolve the question. It routes you to a longer study.
Separately, Q1A(R2) describes stress testing — forced degradation — as a different exercise conducted at temperatures in 10 °C increments above the accelerated condition (50 °C, 60 °C and so on), at 75% RH or greater where appropriate, plus oxidation, photolysis, and susceptibility to hydrolysis across a wide range of pH values. Forced degradation deliberately breaks the molecule. Its purpose is to map the degradation pathways and to prove that the analytical method can resolve the products from the parent peak. It is a method-qualification experiment wearing a stability experiment’s clothes.
The extrapolation rules are written down, and they are tight
ICH Q1E governs what may be inferred from stability data, and it is the document that disposes of the folk arithmetic outright. Extrapolation is permitted only on the assumption that “the same change pattern will continue to apply beyond the period covered by long-term data,” and a retest period or shelf life granted on that basis “should always be verified by additional long-term stability data.”
The permitted margins are numerical. For room-temperature storage with no significant change at the accelerated condition, extrapolation may extend up to twice, but not more than twelve months beyond, the period covered by long-term data. Where significant change occurs at the accelerated condition but not at the intermediate, the allowance drops to one-and-a-half times and not more than six months. For refrigerated products the allowance is one-and-a-half times and no more than six months. For products stored in a freezer, there is no extrapolation at all — the shelf life is based on long-term data, full stop.
Read that last line against a lyophilized peptide stored at −20 °C and the position is unambiguous. The storage condition our own product pages specify is precisely the one for which the guideline permits no extrapolation from accelerated data whatsoever.
Why the Arrhenius shortcut breaks
The folk rule is a crude Arrhenius extrapolation: assume a single rate-limiting chemical step, assume its activation energy is constant across the temperature range, and scale. Both assumptions are doing a great deal of unexamined work.
The published methods that do this properly are considerably more careful. Waterman and colleagues, in Pharmaceutical Research in 2007, set out an isoconversion protocol for solid-state small molecules in which chamber times are set to reach a critical degradant level rather than a fixed duration, temperature and humidity effects are modeled with a humidity-corrected Arrhenius equation treating the two as orthogonal, and experimental imprecision is propagated through a Monte-Carlo simulation rather than ignored. That is what a defensible accelerated prediction looks like: humidity as a modeled variable, uncertainty carried explicitly, and validation against measured shelf lives at the lower conditions. It is not a multiplication.
And that protocol was developed and tested for small-molecule solid dosage forms. A synthetic peptide sits awkwardly between regulatory frameworks — larger and more conformationally complex than the molecules Q1A(R2) was drafted around, smaller and better defined than the recombinant products ICH Q5C addresses. Q5C is worth reading anyway, because it states the principle in the plainest available language: expiration dating “should be based on real-time/real-temperature data,” and primary data supporting a storage period “should be based on long-term, real-time, real-condition stability studies.” Accelerated and stress studies are assigned supporting roles only — validating analytical methods, elucidating the degradation profile, assessing whether an accidental excursion during transport was damaging. Q5C also observes that degradation of these products “may not be governed by the same factors during different intervals of a long storage period,” which is exactly the condition under which a single-mechanism Arrhenius extrapolation stops meaning anything.
A peptide has several competing degradation routes with different temperature dependences. Heating the vial does not accelerate all of them by the same factor. It changes which one dominates.
Forced degradation is the study that is actually worth running
If accelerated studies cannot generate a shelf life, what is the point of stressing a peptide at all? Patel, Vyas and Mehta reviewed forced degradation strategies for therapeutic peptide formulations in the International Journal of Peptide Research and Therapeutics in 2023, and their framing is the right one: forced degradation is an indispensable development tool because peptide degradation behaves differently from small-molecule degradation, and understanding the degradation behavior is what lets a stable formulation be designed in the first place.
The output of a good forced-degradation study is not a date. It is a list: these are the degradation products this sequence forms, this is the chromatographic method that resolves them, this is the stress that produces them fastest. That list is what makes every subsequent purity number trustworthy, because a purity assay that cannot see a degradant will report a clean chromatogram on degraded material.
What this means for a research vial
Our certificates carry no stability section, and this article is a reason to be direct about that rather than quiet. The batch certificate for the Tirzepatide 10MG reference material — report DBAV-TIRZ-10-052926, lot 5966, received 3 June 2026, tested 22 June, reported 23 June — records expected content of 10.00 mg against a measured 10.90 mg, a fill accuracy of 109.0%, and purity of 99.88% by HPLC-UV at 214 nm, with appearance recorded as white lyophilized powder. It carries no accelerated data, no retest date, no expiry, and no stability-indicating method statement. Neither does any other certificate in our catalog, and neither does any research-grade certificate we have examined from any other US supplier.
That is the honest position for the whole category, and it has one genuine practical consequence a purchaser can act on. Since no supplier can hand you a validated shelf life, the variable actually under your control is the length and condition of the uncontrolled interval between synthesis and your freezer. Domestic sourcing shortens that interval: material shipped same-day from our Santa Barbara facility spends days, not weeks, in ambient transit, and does not sit in an international customs queue at whatever temperature the queue happens to be. That is not a stability claim. It is simply the one part of the timeline a US laboratory can measure and shorten.
The rest belongs to your own records. Log the receipt date, log the storage temperature, log the freeze–thaw count, and treat the certificate as what it is — a characterization of the material on the date it was tested, not a forecast of the material in front of you today.
References
- International Council for Harmonisation. Q1A(R2) — Stability Testing of New Drug Substances and Products. Step 4 version, 6 February 2003. Storage-condition tables for drug substance and drug product; definition of significant change; stress testing provisions.
- International Council for Harmonisation. Q1E — Evaluation for Stability Data. Step 4 version, 6 February 2003. Extrapolation limits for room-temperature, refrigerated and frozen storage; requirement for verification by additional long-term data.
- International Council for Harmonisation. Q5C — Stability Testing of Biotechnological/Biological Products. Step 4 version, 30 November 1995. Real-time / real-condition requirement; permitted roles for accelerated and stress studies.
- Waterman KC, Carella AJ, Gumkowski MJ, Lukulay P, MacDonald BC, Roy MC, Shamblin SL — improved protocol and data analysis for accelerated shelf-life estimation of solid dosage forms. Pharmaceutical Research, 2007; 24(4):780–790. DOI 10.1007/s11095-006-9201-4.
- Patel S, Vyas VK, Mehta PJ — a review on forced degradation strategies to establish the stability of therapeutic peptide formulations. International Journal of Peptide Research and Therapeutics, 2023; 29(2):22. DOI 10.1007/s10989-023-10492-8.
- Maple Research Labs batch certificate DBAV-TIRZ-10-052926, lot 5966, issued by Testides Analytical; read directly from the certificate linked on the product page.
All materials supplied by Maple Research Labs are provided for research use only. They are not for human use, not for veterinary use, and not for diagnostic or therapeutic application. Nothing in this article describes administration to people.